Soluble interleukin-2 receptor and interleukin-6 levels: evaluation during cyclosporin A and methotrexate treatment in psoriatic arthritis.
Spadaro
A
A
Institute of Rheumatology, University La Sapienza, Rome, Italy.
Taccari
E
E
Sensi
F
F
Riccieri
V
V
Sili Scavalli
A
A
Zoppini
A
A
D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000097:blood* / Q000188:drug therapy*; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012995:Solubility; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D015850:Interleukin-6; D015375:Receptors, Interleukin-2; D016572:Cyclosporine; D008727:Methotrexate